Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AND...Collaboration and License Agreement • November 9th, 2021 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledNovember 9th, 2021 Company IndustryThis COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 26, 2015 (the “Effective Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 300 Third Street, First Floor, Cambridge, MA 02142 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (“Juno”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 8th, 2018 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 8th, 2018 Company Industry JurisdictionThis COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 26, 2015 (the “Effective Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 300 Third Street, First Floor, Cambridge, MA 02142 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (“Juno”).
AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and between EDITAS MEDICINE, INC. AND JUNO THERAPEUTICS, INC. May 3, 2018Collaboration and License Agreement • October 23rd, 2018 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 23rd, 2018 Company Industry JurisdictionThis AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 3, 2018 (the “Amendment Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 11 Hurley St, Cambridge, MA 02141 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 400 Dexter Avenue North, Suite 1200, Seattle, WA 98109 (“Juno”) and amends and restates that certain Collaboration and License Agreement by and between Editas and Juno (the “Original Agreement”) dated as of May 26, 2015 (the “Original Agreement Effective Date”).